One-year claims analysis comparing inhaled fluticasone propionate with zafirlukast for the treatment of asthma

Journal of Allergy and Clinical Immunology

Volumn 107, Issue 1, 2001, Pages 94-98

  Stempel, David A ^a   Meyer, Jay W ^b   Stanford, Richard H ^c   Yancey, Steve W ^c  

^a VIRGINIA MASON MEDICAL CENTER   (United States)

^b Ingenix Inc   (United States)

^c GLAXOSMITHKLINE   (United States)

Author keywords

Asthma; Asthma costs; Claims data; Fluticasone propionate; Inhaled corticosteroids; Leukotriene modifiers; Retrospective analysis; Zafirlukast

Indexed keywords

CORTICOSTEROID; FLUTICASONE PROPIONATE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; ZAFIRLUKAST;

ARTICLE; ASTHMA; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HEALTH CARE COST; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

EID: 0035144820     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1067/mai.2001.112029     Document Type: Article

References (30)

1. A national estimate of the economic costs of asthma
2. An economic evaluation of asthma in the United States
3. The cost of asthma in the emergency department and hospital
4. Inhaled steroids and the risk of hospitalization for asthma
5. Effect of corticosteroid therapy introduction in asthmatic Medicaid-enrolled children
6. Increased use of inhaled corticosteroids and reduced hospitalizations in adult asthmatics: 11 years' experience in a Japanese hospital
7. First treatment with inhaled corticosteroids and the prevention of admissions to hospital for asthma
8. Decrease in asthma mortality rate in Israel from 1991-1995: Is it related to the use of inhaled corticosteroids?
9. Highlights of the expert panel report II: Guidelines for the diagnosis and management of asthma
10. New US asthma guidelines stress early, aggressive treatment
11. New guidelines on asthma management
12. Inflammation in asthma: The cornerstone of the disease and target of therapy
13. The effect of inhaled fluticasone propionate 100 μ bid compared with oral zafirlukast 20 mg bid on bronchial hyperresponsiveness
14. Inhaled fluticasone propionate and oral zafirlukast in moderate asthma: A clinical and cost comparison
15. A statistical comparison of the efficacy of leukotriene modifiers and inhaled corticosteroids
16. Low-dose inhaled fluticasone propionate versus oral zafirlukast in asthma patients
17. Better asthma symptom control with low-dose inhaled fluticasone propionate than with oral zafirlukast
18. Low-dose inhaled fluticasone propionate versus oral zafirlukast in the treatment of persistent asthma
19. Oral montelukast, inhaled beclomethasone, and placebo for chronic asthma. A randomized, controlled trial
20. Pharmacoeconomic evaluation: Applications in managed care health care formulary decision-making
21. Methodological issues in conducting pharmacoeconomic evaluations: Retrospective and claims database studies
22. Randomized, controlled trials, observational studies, and the hierarchy of research designs
23. Randomized trials or observational tribulations
24. Draft consensus development on pharmacoeconomic analysis: A working paper
25. Outcomes analysis in asthma
26. Use of a pharmacy and medical claims database to document cost centers for 1993 annual asthma expenditures
27. Guidelines for the clinical and economic evaluation of health care technologies
28. The use of administrative data to risk-stratify asthmatic patients
29. Pharmacoeconomic research credibility: A controversial and recurring theme in health outcomes research